17 results

  • Advair

    (fluticasone propionate and salmeterol)
    GlaxoSmithKline LLC
    Usage: ADVAIR DISKUS is indicated for the twice-daily treatment of asthma in patients aged 4 and older and for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for acute bronchospasm relief or for patients not adequately controlled on long-term asthma medications.

  • Advair hfa

    (fluticasone propionate and salmeterol xinafoate)
    GlaxoSmithKline LLC
    Usage: ADVAIR HFA is indicated for the treatment of asthma in adults and adolescents aged 12 and older who are not adequately controlled on long-term asthma medications or require both an inhaled corticosteroid and a long-acting beta2-adrenergic agonist. It is not for acute bronchospasm relief.

  • Anoro ellipta

    (umeclidinium bromide and vilanterol trifenatate)
    GlaxoSmithKline LLC
    Usage: ANORO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for the relief of acute bronchospasm or asthma treatment, and its safety and effectiveness in asthma have not been established.

  • Arnuity ellipta

    (fluticasone furoate)
    GlaxoSmithKline LLC
    Usage: ARNUITY ELLIPTA is indicated for the maintenance treatment of asthma in adults and children aged 5 years and older, but is not intended for the relief of acute bronchospasm.

  • Benlysta

    (belimumab)
    GlaxoSmithKline LLC
    Usage: BENLYSTA (belimumab) is indicated for patients aged 5 and older with active systemic lupus erythematosus and active lupus nephritis, both receiving standard therapy. Its efficacy in severe active central nervous system lupus is not evaluated, hence it is not recommended for such cases.

  • Blujepa (gepotidacin)

    (gepotidacin)
    GlaxoSmithKline LLC
    Usage: BLUJEPA is indicated for treating uncomplicated urinary tract infections in females aged 12 years and older, caused by specific susceptible bacteria. It is also recommended to reduce the risk of drug-resistant bacteria by using it only against confirmed or strongly suspected infections from these organisms.

  • Breo ellipta

    (fluticasone furoate and vilanterol trifenatate)
    GlaxoSmithKline LLC
    Usage: BREO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients aged 5 years and older. It is not to be used for the relief of acute bronchospasm.

  • Incruse ellipta

    (umeclidinium)
    GlaxoSmithKline LLC
    Usage: INCRUSE ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients.

  • Jalyn

    (dutasteride and tamsulosin hydrochloride)
    GlaxoSmithKline LLC
    Usage: JALYN (dutasteride and tamsulosin hydrochloride) is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men. It is not approved for the prevention of prostate cancer.

  • Jemperli

    (dostarlimab)
    GlaxoSmithKline LLC
    Usage: JEMPERLI is indicated for adults with primary advanced or recurrent endometrial cancer (EC) in combination with carboplatin and paclitaxel, followed by JEMPERLI alone. It also treats adults with mismatch repair deficient recurrent or advanced solid tumors that have progressed after prior treatment and lack satisfactory alternatives.